Sherman WH, et al. - Researchers performed an analysis of patients presenting with locally advanced pancreatic adenocarcinoma deemed unresectable and documented the presenting tumor size, extent of vascular involvement, tumor markers, response to neoadjuvant gemcitabine (G), docetaxel (T), and capecitabine (X) with or without additional chemoradiotherapy with GX on R0 resection rates (≥2 mm margins), and survival. They observed achievement of R0 resection, the goal of neoadjuvant treatment, in 70% of patients presenting with locally advanced pancreatic cancer. The median disease-free survival of 31 months was evident. They identified no association with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), cancer antigen test 19-9 (CA 19-9), degree of tumor regression on scan, fall in CA 19-9, or SUV on positron emission tomography (PET) scan and subsequent survival.